Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Sourcing professions ascertain that fill checks are performed at logical points in the process and that operations are overseen and observed by quality personnel
Different Marketing Claims Wegovy was aggressively marketed directly to consumers for weight loss Ozempic marketing technically focused on diabetes but implied weight benefits Social media influencers promoted both (often Ozempic off-label) Marketing materials affect what representations were made to you Example Case Scenarios Scenario A: Type 2 Diabetic on Ozempic Patient: 58-year-old with 10-year diabetes history Prescription: Ozempic 1.0 mg weekly for A1C control Result: Developed severe gastroparesis requiring feeding tube Legal claim: Even for approved use, warnings about gastroparesis were inadequate Scenario B: Weight Loss Patient on Ozempic (Off-Label) Patient: 42-year-old seeking to lose 40 pounds, no diabetes Prescription: Ozempic 2.0 mg (prescribed off-label by weight loss clinic) Result: Chronic vomiting, diagnosed with gastroparesis Legal claim: Off-label promotion and inadequate warnings for weight-loss use Scenario C: Obesity Patient on Wegovy Patient: 35-year-old with BMI 38, prescribed for weight management Prescription: Wegovy escalated to 2.4 mg Result: Intestinal blockage requiring emergency surgery Legal claim: Despite approved use, risks were not adequately disclosed All three scenarios may have valid legal claims , but the specific arguments and evidence will differ
The most commonly observed adverse events (incidence of 5% and twice that of placebo) were oily spotting, flatus with discharge, fecal urgency, fatty/oily stool, oily evacuation, increased defecation and fecal incontinence
EGF-receptor inhibition may prevent tumor cell dissemination
